Traveloka 6.6 Mid Year Sale: Up to S$66 Off Flights, Hotels and Attractions for Singapore Travelers
Traveloka's 6.6 Mid Year Sale Unlocks $66 Sitewide Discounts and 1-for-1 Attraction Deals SINGAPORE, June 1, 2026 /PRNewswire/ -- Traveloka, Southeast Asia's leading travel tech platform, today announced its 6.6 Mid Year Sale that runs from 2 to 9...
Deloitte appoints Robert Hillard as Asia Pacific Chief Executive Officer
HONG KONG, June 1, 2026 /PRNewswire/ -- Deloitte Asia Pacific today announced the appointment of Robert Hillard as Asia Pacific Chief Executive Officer, commencing a four-year term. Mr Hillard's appointment was endorsed by partners across Asia...
BofA Securities Asia Forum Gathers Global Investors Amid Surge in Hedge Funds Allocations
Key points BofA Securities hosted its fourth annual Asia Alternatives Forum, bringing together more than 20 hedge fund managers and 120 institutional allocators. Allocators of approximately $700 billion in hedge fund capital discussed market...
UOB and FPT sign MoU to advance AI, technology transformation and financial innovation opportunities
SINGAPORE, June 1, 2026 /PRNewswire/ -- UOB and global technology corporation FPT have signed a Memorandum of Understanding (MoU) to explore strategic collaboration opportunities in artificial intelligence (AI), digital and technology...
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
SHANGHAI, June 1, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis results of satricabtagene autoleucel...
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an objective response rate (ORR) of 81.3% and a disease...
D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4 months in first-line KRAS G12C–mutant NSCLC (n=41) across all PD-L1 expression levels Combination of elisrasib with pembrolizumab achieves an ORR of 81.3% in first-line KRAS...
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview
TAIPEI, June 1, 2026 /PRNewswire/ -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today...